| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.05.
| Hot Stock: Inovio Biomedical, Shares Gain 12.8% | | 5 | SmarTrend |
| 21.05.
| Inovio Pharmaceuticals meldet Erfolg in Phase I gegen Vogelgrippe Virus | | 3 | Proactive Investors DE |
| 17.05.
| Inovio Pharmaceuticals advances universal flu vaccine strategy with avian flu phase I study | | 3 | Proactive Investors |
| 16.05.
| Inovio (INO) Reports Encouraging Data for SynCon Vaccine in Generating HAI Titers | | 1 | StreetInsider.com |
| 16.05.
| Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial | | 24 | PR Newswire |
| BLUE BELL, Pa., May 16, 2012 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different...
Mehr lesen zu:
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial | |
| 15.05.
| Inovio Pharmaceuticals to Present at SPI 2012 | | 13 | PR Newswire |
| BLUE BELL, Pa., May 15, 2012 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company and participate...
Mehr lesen zu:
Inovio Pharmaceuticals to Present at SPI 2012 | |
| 14.05.
| Inovio Pharma in Gesprächen zu neuer Finanzerhebung | | 4 | Proactive Investors DE |
| 10.05.
| Inovio Biomedical Down 10.2%, Shares Slide into the Red | | 5 | SmarTrend |
| 10.05.
| Inovio Pharma Q1 Loss Widens | | 55 | AFX News |
| WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO) posted
first-quarter net loss attributable to common stockholders of $8.3 million or
$0.06 per share, wider than $2.4 million or...
Mehr lesen zu:
Inovio Pharma Q1 Loss Widens | |
| 10.05.
| Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results | | 41 | PR Newswire |
| BLUE BELL, Pa., May 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended March 31, 2012.
Total revenue was $1.7 million for...
Mehr lesen zu:
Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results | |
| 02.05.
| Inovio Pharmaceuticals Wirkstoff VGX-3100 erhält US Patentschutz | | 4 | Proactive Investors DE |
| 02.05.
| Inovio wins US patent for cervical dysplasia, cancer vaccine | | - | Pharma Bus Review |
| 01.05.
| Inovio Pharma (INO) Gets U.S. Patent for SynCon | | 1 | StreetInsider.com |
| 01.05.
| Inovio Pharma Awarded U.S. Patent Covering SynCon Vaccine For Cervical Dysplasia | | 60 | AFX News |
| WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) said the United
States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering
Inovio's SynCon vaccine for cervical...
Mehr lesen zu:
Inovio Pharma Awarded U.S. Patent Covering SynCon Vaccine For Cervical Dysplasia | |
| 01.05.
| Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer | | 45 | PR Newswire |
| BLUE BELL, Pa., May 1, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering...
Mehr lesen zu:
Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer | |
| 03.04.
| Inovio Pharmaceuticals erhält Zuschuss vom US Militär für Forschungsprogramm | | 6 | Proactive Investors DE |
| 02.04.
| Inovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program | | 41 | PR Newswire |
| BLUE BELL, Pa., April 2, 2012 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to...
Mehr lesen zu:
Inovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program | |
| 27.03.
| Inovio Appoints Retired Merck Vaccines President Dr. Adel Mahmoud to its Board of Directors | | 63 | PR Newswire |
| BLUE BELL, Pa., Mar. 27, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today Dr. Adel Mahmoud, a global infectious disease and vaccines expert, has been appointed...
Mehr lesen zu:
Inovio Appoints Retired Merck Vaccines President Dr. Adel Mahmoud to its Board of Directors | |
| 26.03.
| Inovio Pharmaceuticals Reports Grant Of Patent For H1N1 Influenza Vaccine | | 41 | AFX News |
| WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) Monday reported
that the U.S. Patent and Trademark Office granted the Trustees of The
University of Pennsylvania a patent which...
Mehr lesen zu:
Inovio Pharmaceuticals Reports Grant Of Patent For H1N1 Influenza Vaccine | |
| 26.03.
| Inovio Receives U.S. Patent for SynCon® H1N1 Influenza Universal Vaccine | | 77 | PR Newswire |
| BLUE BELL, Pa., March 26, 2012 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering...
Mehr lesen zu:
Inovio Receives U.S. Patent for SynCon® H1N1 Influenza Universal Vaccine | |
